Actavis Acquires Allergan

Actavis has completed its acquisition of Allergan in a cash and equity transaction valued at approximately $70.5 billion. The merger makes Actavis one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015.

The company now has six franchises, including those in eye care, neurosciences/CNS and medical aesthetics/dermatology/plastic surgery, as well as a portfolio of world-renowned brands including BOTOX, RESTASIS, JUVEDERM, NAMENDA XR, LINZESS and Lo Loestrin Fe.

“Our combined company will be built around a customer-focused commitment to partnering with physicians, pharmacists and patients to deliver innovative treatments and enhance access to important therapies around the world,” said Brent Saunders, CEO and president of Actavis.

More in News